Apr. 15 at 12:22 PM
$ESPR @ShortESPR
$ESPR – On the
$3–5B (potentially higher) buyout valuation:
Bempedoic acid is already approved and launching in all major markets, with the U.S. as the biggest untapped opportunity. A big pharma acquirer could easily look past our ~155 sales reps and see what 3,000+ reps could achieve in ramping up adoption.
The guideline battles are largely behind us, with multiple approved indications now backed by strong recommendations.
Compare that to clinical-stage companies like NewAmsterdam Pharma (
$NAMS) — pre-revenue, selling virtually nothing, yet valued at nearly
$4B today on pure future potential.
Acquisitions are priced on growth upside, not current sales. Owning bempedoic acid would give any CV/lipid player a dominant trio (statin + PCSK9 + bempedoic acid) and block competitors. Sometimes you overpay to secure a strategic asset — this one could easily be worth well over
$5B to the right buyer. Patience.
